2021 American Transplant Congress
Therapeutic Enoxaparin Dosing in Lung Transplant Recipients
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Enoxaparin 1 mg/kg subcutaneously every 12 hours for therapeutic anticoagulation is known to increase rates of supratherapeutic anti-Xa levels in lung transplant recipients (LTRs).…2021 American Transplant Congress
Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay
*Purpose: Development of donor‐specific antibodies (DSA) is associated with poor outcomes in lung transplantation. Patients who are presented with at least probable AMR require treatment;…2021 American Transplant Congress
Proxies of Ischemia Time Do Not Predict 1-Year Posttransplant Survival
*Purpose: A barrier to broader distribution of donor organs is a concern that increased donor-to-recipient (DtR) distances could increase ischemia times and compromise posttransplant (PT)…2021 American Transplant Congress
Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Data from the US Scientific Registry of Transplant Recipients (SRTR)
*Purpose: There is currently no FDA approved immunosuppressive regimen for lung transplant (Tx) recipients; however, patients routinely receive a calcineurin inhibitor-based regimen. The SRTR database…2021 American Transplant Congress
Elexacaftor/ivacaftor/tezacaftor in Lung Transplant Recipients: A Case Series
1University of Chicago Medicine, Chicago, IL, 2Roosevelt University, Chicago, IL
*Purpose: Little data is published describing the safety or efficacy of elexacaftor/ivacaftor/tezacaftor in lung transplant recipients. Even though it is not expected to offer pulmonary…2021 American Transplant Congress
Lung Transplant Recipients Developing Early DSAs are Characterized by a Shift Towards Memory B Cells Directly After Transplantation
*Purpose: After lung transplantation (LTx), the development of early donor HLA-specific antibodies (eDSA) is associated with antibody-mediated rejection (AMR) and poor graft survival. Since 2013,…2021 American Transplant Congress
Textbook Outcome: A Novel Metric in Lung Transplantation Outcomes
*Purpose: Lung transplant programs are typically assessed based on 1-/3-year survival, however other factors such as quality of life, freedom from rejection and oxygen, etc.,…2021 American Transplant Congress
Use of Granulocyte Colony Stimulating Factor After Lung Transplantation is Not Associated with Increased Likelihood of Acute Cellular Rejection
*Purpose: The cause of neutropenia in lung transplant recipients is multifactorial, including medications, viral infections, and antecedent disease. Granulocyte colony-stimulating factor (G-CSF) is commonly used…2021 American Transplant Congress
Donor Lymphocytes in Peripheral Blood of Patients After Lung Transplantation Comprise High Frequencies of Killer Cell Immunoglobulin-like Receptor-positive T and NK Cell Subsets
*Purpose: For end-stage lung diseases, lung transplantation (LuTx) is the only curative treatment option. However, acute and chronic rejections are major limitations. Thus, a deeper…2021 American Transplant Congress
Acute Kidney Injury After Lung Transplantation: Incidence, Risk Factors and Outcomes. Results from a Monocentric Retrospective Cohort Study
*Purpose: Acute kidney Injury (AKI) occurs in more than 50% of patients after lung transplantation (LTx). Our purpose was to define incidence, risk factors and…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 42
- Next Page »